CytRx to Present at the Jefferies 2015 Global Healthcare Conference

May 26, 2015, 09:00 ET from CytRx Corporation

LOS ANGELES, May 26, 2015 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Steven A. Kriegsman, Chairman and Chief Executive Officer, and David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at the Jefferies 2015 Global Healthcare Conference on Tuesday, June 2, 2015 at 1:30 p.m. Eastern Time. The conference will take place at the Grand Hyatt in New York, NY.

A live and archived webcast of the presentation will be available on the Company's website at www.cytrx.com/investors/presentations.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology.  CytRx currently is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx has initiated under a special protocol assessment a pivotal Phase 3 global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy, and has announced that it has received approval from the FDA to continue dosing patients with aldoxorubicin until disease progression in that clinical trial. CytRx is currently evaluating aldoxorubicin in a global Phase 2b clinical trial in small cell lung cancer, a Phase 2 clinical trial in HIV-related Kaposi's sarcoma, a Phase 2 clinical trial in patients with late-stage glioblastoma (brain cancer), a Phase 1b trial in combination with ifosfamide in patients with soft tissue sarcoma, and a Phase 1b trial in combination with gemcitabine in subjects with metastatic solid tumors. CytRx has completed a global Phase 2b clinical trial with aldoxorubicin as a first-line therapy for soft tissue sarcomas, a Phase 1b/2 clinical trial primarily in the same indication, a Phase 1b clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. CytRx plans to expand its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, based on novel linker technologies that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites.  For more information about CytRx Corporation, visit www.cytrx.com.

Investor Relations: Argot Partners Michelle Carroll 212.600.1902 michelle@argotpartners.com

Legend Securities John Columbia 800-385-5790 ext 164 718-233-2677 (Direct) jcolumbia@legendsecurities.com 

Media: Argot Partners Eliza Schleifstein 973.361.1546 eliza@argotpartners.com

Company Contact: CytRx Corporation David J. Haen Vice President, Business Development and Investor Relations 310-826-5648, x304 dhaen@cytrx.com

SOURCE CytRx Corporation



RELATED LINKS

http://www.cytrx.com